Christopher Paul  Riley net worth and biography

Christopher Riley Biography and Net Worth

EVP, Biotechnology Group and CEO, Cytiva of Danaher

As Executive Vice President of Danaher’s Biotechnology Platform, Chris provides operational and strategic leadership for Cytiva and its portfolio of businesses.

Chris Riley is an experienced business operator and growth-oriented strategist with a track record of innovating and applying the Danaher Business System to global Diagnostics and Life Sciences companies.

Chris joined Danaher in 2007 and has served in multiple operating and strategy roles of increasing responsibility.  In 2019, Chris was appointed Danaher Vice President and Group Executive, Diagnostics, and in 2022, he was appointed Danaher Vice President and Group Executive, Genomic Medicines Group.  Prior to joining Danaher, he worked for Boston Consulting Group as a core member of their Operations and Strategy practice areas.

Chris holds a Bachelor of Science with Honors in Mechanical Engineering from the University of Illinois and an MBA from the Kellogg Graduate School of Management at Northwestern University.

What is Christopher Paul Riley's net worth?

The estimated net worth of Christopher Paul Riley is at least $2.95 million as of April 30th, 2025. Mr. Riley owns 15,179 shares of Danaher stock worth more than $2,950,206 as of June 18th. This net worth approximation does not reflect any other assets that Mr. Riley may own. Learn More about Christopher Paul Riley's net worth.

How do I contact Christopher Paul Riley?

The corporate mailing address for Mr. Riley and other Danaher executives is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. Danaher can also be reached via phone at (202) 828-0850 and via email at [email protected]. Learn More on Christopher Paul Riley's contact information.

Has Christopher Paul Riley been buying or selling shares of Danaher?

Within the last three months, Christopher Paul Riley has sold $3,129,390.00 in shares of Danaher stock. Most recently, Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a transaction totalling $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at $3,005,442. Learn More on Christopher Paul Riley's trading history.

Who are Danaher's active insiders?

Danaher's insider roster includes Rainer Blair (President, CEO & Director), Daniel Comas (EVP), Georgeann Couchara (SVP), William Daniel (EVP), Brian Ellis (SVP), Linda Filler (Director), Jose-Carlos Gutierrez-Ramos (SVP), Linda Hefner (Director), Jennifer Honeycutt (EVP), Thomas Joyce, Jr. (CEO), William King (SVP), Angela Lalor (SVP), Angela Lalor (SVP), Teri List (Director), Walter Lohr (Director), Robert Lutz (CAO), Matthew McGrew (CFO), Mitchell Rales (Chairman), Steven Rales (Co-Founder, Chairman), Daniel Raskas (SVP), Christopher Riley (EVP, Biotechnology Group and CEO, Cytiva), John Schwieters (Director), Alan Spoon (Director), Raymond Stevens (Director), Joakim Weidemanis (EVP), and Elias Zerhouni (Director). Learn More on Danaher's active insiders.

Are insiders buying or selling shares of Danaher?

In the last twelve months, insiders at the conglomerate sold shares 8 times. They sold a total of 1,311,164 shares worth more than $261,374,363.72. The most recent insider tranaction occured on May, 12th when Chairman Steven M Rales sold 1,250,000 shares worth more than $245,925,000.00. Insiders at Danaher own 11.2% of the company. Learn More about insider trades at Danaher.

Information on this page was last updated on 5/12/2025.

Christopher Paul Riley Insider Trading History at Danaher

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2025Sell15,805$198.00$3,129,390.0015,179View SEC Filing Icon  
See Full Table

Christopher Paul Riley Buying and Selling Activity at Danaher

This chart shows Christopher Paul Riley's buying and selling at Danaher by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Danaher Company Overview

Danaher logo
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Read More

Today's Range

Now: $194.36
Low: $193.12
High: $197.00

50 Day Range

MA: $193.42
Low: $180.64
High: $204.85

2 Week Range

Now: $194.36
Low: $171.00
High: $281.70

Volume

3,236,239 shs

Average Volume

3,488,121 shs

Market Capitalization

$139.10 billion

P/E Ratio

37.74

Dividend Yield

0.65%

Beta

0.77